Nektar Therapeutics (NKTR) Operating Expenses (2010 - 2026)

Nektar Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $49.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 1018.92% year-over-year to $49.9 million; the TTM figure through Mar 2026 stood at $147.0 million (up 219.76% YoY), while the FY2025 annual figure was $195.3 million, up 422.19% from the prior year.
• Operating Expenses for Q1 2026 stood at $49.9 million, up from $49.5 million in the prior quarter.
• The five-year high for Operating Expenses was $174.4 million in Q2 2022, with the low at -$151.4 million in Q4 2024.
• The 5-year median for Operating Expenses is $49.9 million (2026), against an average of $41.1 million.
• The sharpest annual moves came in 2023 and 2026: Operating Expenses slumped 297.43% in 2023, then jumped 1018.92% in 2026.
• Nektar Therapeutics' Operating Expenses stood at $74.5 million in 2022, then plunged by 297.43% to -$147.1 million in 2023, then dropped by 2.94% to -$151.4 million in 2024, then jumped by 132.68% to $49.5 million in 2025, then gained by 0.9% to $49.9 million in 2026.
• Business Quant data shows NKTR's Operating Expenses at $49.9 million in Q1 2026, $49.5 million in Q4 2025, and $43.5 million in Q3 2025.